Public drug plan costs rose by nearly 2% in FY2016-2017
Public drug plan expenditures increased by an additional 1.9% in fiscal year 2016-17, following growth of 10.8% the previous year, reaching a total of $10.7 billion, according to a Patented Medicine Prices Review Board’s (PMPRB) report . The increase